Anjarium Biosciences

Switzerland
Schlieren, Zurich, Switzerland, 8952

Company profile

Anjarium Biosciences company profile

Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address a range of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2017-01-01, Year

Headquarters

Postal code
8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$60.4M
Last funding
Series A / $60.4M / 2021-09-15
Last equity funding
Series A / $60.4M
Investors
6
Lead investors
2
Founders
1
Articles
20

Founders and investors

Founders

Joel de Beer

Lead investors

AbingworthGimv

Investors

AbingworthGimvOmega FundsPfizer Venture InvestmentsSurveyor Capital